Mark J. Zweifel
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark J. Zweifel.
Biofutur | 1997
Robin D. G. Cooper; Bret E. Huff; Thalia I. Nicas; John Thomas Indianapolis Quatroche; Michael J. Rodriguez; Nancy June Snyder; Michael A. Staszak; Richard Craig Thompson; Stephen Charles Wilkie; Mark J. Zweifel
The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity aginst a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.
Bioorganic & Medicinal Chemistry Letters | 2000
James Andrew Jamison; Stuart Levy; Xicheng Sun; Doug Zeckner; William L. Current; Mark J. Zweifel; Michael J. Rodriguez; William Wilson Turner; Shu-Hui Chen
We have described herein the syntheses of three novel series of aromatic ring containing pseudomycin side-chain analogues. Preliminary biological evaluations of these analogues clearly indicate that it is possible to synthesize rigid pseudomycin side-chain analogues without compromising in vitro antifungal activity.
Bioorganic & Medicinal Chemistry Letters | 2000
Shu-Hui Chen; Xicheng Sun; Robert Boyer; Jonathan W. Paschal; Doug Zeckner; William L. Current; Mark J. Zweifel; Michael J. Rodriguez
A series of aliphatic side-chain analogues of pseudomycin was synthesized and evaluated during the course of our side-chain SAR effort. We found that several of the pseudomycin side-chain analogues (e.g., 10) exhibited good in vitro activity against all three major fungi responsible for systemic fungal infections.
Tetrahedron Letters | 1996
Michael J. Rodriguez; Mark J. Zweifel
Abstract The retro-aldol reaction of R106-1 (LY295337), 1 using trimethylamine N-oxide (TNO) facilitates the removal of the tertiary hydroxy group generating R106-sarcosine, 2 a key synthetic intermediate. The reagent is highly reproducible and provides high yields with no major side products. A side by side comparison of TNO vs. traditional bases is described.
Journal of Labelled Compounds and Radiopharmaceuticals | 1996
Michael J. Rodriguez; Mark J. Zweifel
A unique semisynthetic pathway has been used as a route to acquire radiolabeled material of a complex natural product, R106. The retro-aldol reaction of R106-1 gave a key intermediate R106-sarcosine that was used in a subsequent aldol reaction to incorporate acetone-[2- 14 C].
The Journal of Antibiotics | 1996
Robin D. G. Cooper; Nancy June Snyder; Mark J. Zweifel; Michael A. Staszak; Stephen Charles Wilkie; Thalia I. Nicas; Deborah L. Mullen; Thomas F. Butler; Michael J. Rodriguez; Bret E. Huff; Richard Craig Thompson
Antimicrobial Agents and Chemotherapy | 1996
Thalia I. Nicas; Deborah L. Mullen; Jane E. Flokowitsch; David A. Preston; Nancy June Snyder; Mark J. Zweifel; Stephen Charles Wilkie; Michael J. Rodriguez; Richard Craig Thompson; Robin D. G. Cooper
The Journal of Antibiotics | 1998
Michael J. Rodriguez; Nancy June Snyder; Mark J. Zweifel; Stephen Charles Wilkie; Douglas Richard Stack; Robin D. G. Cooper; Thalia I. Nicas; Deborah L. Mullen; Thomas F. Butler; Richard Craig Thompson
Archive | 1997
Robin D. G. Cooper; Michael J. Rodriguez; Nancy June Snyder; Mark J. Zweifel
The Journal of Antibiotics | 1996
Michael J. Rodriguez; Mark J. Zweifel; James D. Farmer; Robert S. Gordee; Richard J. Loncharich